25716-58-9

Upstream product

• 1204408-17-2 2-methyl-6-hydroxy-5-prop-2-yn-1-ylpyrimidin-4(3H)-one 
• 17920-23-9 diethyl propargylmalonate 
• 1204408-17-2 2-Methyl-5-prop-2-yn-1-ylpyrimidine-4,6-diol 
• 26035-66-5 2-methyl-5-(2-oxo-propyl)-1H-pyrimidine-4,6-dione 
• 25716-54-5 2,6-dimethylfuro[2,3-d]pyrimidin-4(3H)-one 

Downstream Products

• 1392817-31-0 2,6-dimethyl-N-[4-(methylsulfanyl)phenyl]furo[2,3-d]pyrimidin-4-amine 
• 1614235-10-7 N-ethyl-N-(4-methoxyphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine 
• 1614235-11-8 N-(4-methoxyphenyl)-2,6-dimethyl-N-propylfuro[2,3-d]pyrimidin-4-amine 
• 1614235-12-9 N-butyl-N-(4-methoxyphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine 
• 1614235-13-0 N-(4-methoxyphenyl)-2,6-dimethyl-N-(propan-2-yl)furo[2,3-d]pyrimidin-4-amine 
• 1614235-02-7 2,6-dimethyl-N-phenylfuro[2,3-d]pyrimidin-4-amine 
• 1614235-04-9 N-(3-ethynylphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine 
• 1614235-05-0 2,6-dimethyl-N-[4-(trifluoromethyl)phenyl]furo[2,3-d]pyrimidin-4-amine 
• 1614235-06-1 N-(3-chloro-4-fluorophenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine 
• 1614235-07-2 N-(4-chlorophenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine 
• 1614235-09-4 N-(4-methoxyphenyl)-2,6-dimethylfuro[2,3-d]pyrimidin-4-amine 
• 1204408-18-3 N-(4-methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

BAX INHIBITORS AND USES THEREOF

A compound having formula (I) or (II) for use inhibiting Bax mediated cell death and/or apoptosis.

RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF

The present disclosure relates to radiolabeled compounds and methods of uses for diagnosis, monitoring, and treatment of various degenerative neurological disorders, neuropsychiatric disorders, brain injuries, vascular diseases, and cancers. Radiolabeled compounds for imaging of microtubules or microtubules and other targets using positron-emission tomography (PET) are specifically disclosed.

CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS

The present invention provides conformationally restricted 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidine compounds and pharmaceutical compositions comprising these compounds. Preferably, the compounds exhibit dual inhibition of microtubule assembly and

The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2, 3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents

The design, synthesis and biological evaluations of fourteen 4-substituted 2,6-dimethylfuro[2,3-d]pyrimidines are reported. Four compounds (11-13, 15) inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor

BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT

Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor re

BICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF

The present invention provides bicyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor a